Table 3 Crosstabulation: TNM-classification/tumor entity
From: Prognostic factors and outcome of Liposarcoma patients: a retrospective evaluation over 15 years
Tumor entity | Total | ||||||
|---|---|---|---|---|---|---|---|
ALT | DLS | MLS | PLS | LSM | |||
TNM-classification | pT1a, pNx, pMx | 1 | 0 | 0 | 2 | 0 | 3 |
pT1b, pNx, pMx | 0 | 2 | 0 | 0 | 0 | 2 | |
pT2a, pNx, pMx | 5 | 0 | 4 | 1 | 0 | 10 | |
pT2b, pNx, pMx | 46 | 8 | 20 | 5 | 1 | 80 | |
pT2b, pNx, cM1 | 0 | 1 | 1 | 0 | 0 | 2 | |
kein TNM vorhanden | 1 | 2 | 3 | 1 | 0 | 7 | |
pT2, pNx, pMx | 0 | 0 | 1 | 0 | 0 | 1 | |
rpT2b, Nx, Mx | 0 | 1 | 4 | 0 | 0 | 5 | |
ypT2b, pNx, pMx | 1 | 5 | 4 | 1 | 0 | 11 | |
subfascial | 2 | 2 | 3 | 2 | 0 | 9 | |
Total | 56 | 21 | 40 | 12 | 1 | 130 | |